Citalopram EP Impurity A Reference Standard: Applications in Pharmaceutical Analysis

In pharmaceutical quality control, the identification and control of related substances are essential for demonstrating the purity, consistency, safety, and stability of an active pharmaceutical ingredient (API) and its finished dosage forms. For selective serotonin reuptake inhibitor (SSRI) medicines such as citalopram, impurity profiling is an important component of analytical development, quality control, process optimization, and regulatory documentation.

Citalopram EP Impurity A Reference Standard is an analytical reference material used to support the identification and quantitative evaluation of a specific citalopram-related compound. Chemicea Pharmaceuticals supplies this reference standard for research and analytical applications, helping pharmaceutical manufacturers, contract research organizations (CROs), analytical laboratories, and quality-control teams perform reliable impurity investigations.

Chemicea identifies Citalopram EP Impurity A with CAT No. CP-C23001 and CAS No. 64372-56-1. The compound has the molecular formula C20H23FN2O2 and molecular weight 342.41 g/mol. It is also known as Citalopram Amide and is associated with Citalopram USP Related Compound A.

Understanding Citalopram EP Impurity A

Citalopram is an SSRI pharmaceutical compound used in the management of depression and certain anxiety-related conditions. During pharmaceutical manufacturing, storage, formulation, or handling, chemically related substances can arise from synthetic processes, side reactions, degradation pathways, or other transformations.

Citalopram EP Impurity A is chemically identified as (1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide. Its structural similarity to citalopram makes an appropriate analytical reference standard particularly useful when developing chromatographic methods capable of distinguishing the impurity from the API and other related compounds.

Reference standards provide analysts with a defined material against which an unknown peak can be compared. This is particularly important when impurity concentrations are low and accurate peak identification is required.

Pharmacopoeial analytical procedures commonly rely on reference substances for the identification or control of related substances. For example, pharmacopoeial documentation for citalopram-related analysis demonstrates the importance of chromatographic separation and reference materials in impurity testing.

Why Reference Standards Are Important in Pharmaceutical Analysis

A reference standard is more than simply a chemically characterized compound. It functions as an analytical benchmark that allows laboratories to establish the identity and behavior of a target substance under defined analytical conditions.

For impurity analysis, reference standards can support:

• Identification of impurity peaks by retention time

• Method development and optimization

• System suitability evaluation

• Quantitative impurity determination

• Specificity and selectivity studies

• Forced-degradation investigations

• Stability-indicating method development

• Analytical method validation

• Comparative chromatographic studies

• Regulatory and quality documentation

When an analytical laboratory observes an unknown peak in a citalopram sample, comparison with Citalopram EP Impurity A Reference Standard can help determine whether the peak corresponds to the specified impurity.

This reduces ambiguity during chromatographic interpretation and provides greater confidence in impurity identification.

Applications of Citalopram EP Impurity A Reference Standard

1. HPLC Method Development

High-performance liquid chromatography (HPLC) remains one of the most widely used techniques for pharmaceutical impurity analysis. A suitable reference standard allows analysts to establish the retention characteristics of Citalopram EP Impurity A under a selected chromatographic method.

During method development, laboratories can inject the impurity standard independently and alongside citalopram API samples. This helps determine whether the analytical method provides adequate separation between the impurity and the principal API peak.

Chromatographic parameters such as mobile-phase composition, column chemistry, flow rate, column temperature, detection wavelength, and gradient conditions can subsequently be optimized to achieve suitable resolution.

Pharmacopoeial citalopram-related procedures demonstrate the use of liquid chromatography for controlling related substances, reinforcing the importance of appropriate chromatographic separation in citalopram analysis.

2. Impurity Identification

One of the most important applications of a reference standard is peak identification.

During routine HPLC analysis, an unexpected chromatographic peak may be observed in a citalopram API or finished-product sample. Retention time comparison with a Citalopram EP Impurity A standard can provide an initial indication of the identity of that peak.

However, retention time alone should not be considered conclusive structural proof. Laboratories may combine chromatographic comparison with orthogonal techniques such as LC-MS, NMR, IR, or other appropriate analytical methods.

Chemicea's analytical characterization approach includes techniques such as HPLC, mass spectrometry, ^1H NMR, IR, and TGA depending on the nature and requirements of the reference material.

3. Quantitative Determination of Related Substances

Reference standards are also important when laboratories need to determine the concentration of a specific impurity.

An accurately characterized impurity standard can be used to prepare calibration or reference solutions. The response obtained from the impurity can then be compared with the response generated by the corresponding peak in the test sample.

Pharmacopoeial citalopram procedures demonstrate how impurity peak responses and reference solutions can be used for related-substance calculations.

The exact calculation procedure, response factor, concentration, and acceptance criterion should always be established according to the applicable pharmacopoeial monograph, validated analytical procedure, or approved specification.

4. Stability Studies

Pharmaceutical products can undergo chemical changes during long-term storage, accelerated stability testing, or exposure to environmental stresses.

Stability studies therefore frequently involve monitoring the formation or progression of related substances over time.

Citalopram EP Impurity A Reference Standard can assist laboratories in determining whether a chromatographic peak appearing during stability testing corresponds to the target impurity.

This supports the development of stability-indicating analytical methods and helps pharmaceutical scientists understand impurity profiles throughout the product's shelf life.

5. Forced-Degradation Studies

Forced degradation is commonly performed during analytical method development to challenge an API or drug product under conditions such as acidic, basic, oxidative, thermal, or photolytic stress.

The objective is not simply to generate degradation products, but to demonstrate that the analytical method can adequately distinguish the API from its degradation products and other related substances.

A Citalopram EP Impurity A reference material can be particularly useful when investigating whether a degradation-related chromatographic peak corresponds to the target compound.

6. Analytical Method Validation

Analytical method validation evaluates characteristics such as specificity, precision, accuracy, linearity, range, detection capability, and robustness, as applicable to the intended procedure.

An impurity reference standard can contribute directly to several of these studies. For example, analysts may use known concentrations of Citalopram EP Impurity A to evaluate method response, linearity, precision, and recovery.

The use of a well-characterized reference material strengthens the analytical evidence generated during method development and validation.

Role in Pharmaceutical Quality Control

For pharmaceutical manufacturers, impurity control is closely connected with batch-to-batch consistency and product quality.

Citalopram API manufacturers may use impurity standards during process development to understand the formation of process-related substances. Quality-control laboratories can use them for routine testing, while formulation manufacturers may apply them during finished-product analysis.

The value of a reference standard therefore extends across the pharmaceutical development lifecycle—from early process research through commercial quality control.

Official pharmacopoeial systems also distinguish between reference substances and routine working standards. The Indian Pharmacopoeia Commission notes that secondary or working standards may be used for routine analysis when appropriately standardized against official reference substances.

Chemicea Citalopram EP Impurity A Reference Standard

Chemicea Pharmaceuticals provides Citalopram EP Impurity A as part of its pharmaceutical impurity reference-standard portfolio.

Parameter	Details
Product	Citalopram EP Impurity A
CAT No.	CP-C23001
CAS No.	64372-56-1
Molecular Formula	C20H23FN2O2
Molecular Weight	342.41 g/mol
Synonyms	Citalopram Amide; Citalopram USP Related Compound A
Application	Pharmaceutical analytical research

Chemicea's available certificate information demonstrates characterization using techniques including LC-MS, HPLC, and ^1H NMR. A representative Chemicea COA also specifies storage under tightly closed conditions and recommends refrigeration at 2–8°C for the material.

Because storage requirements can vary according to the specific batch and material, laboratories should always follow the current product COA and accompanying documentation.

Analytical Characterization at Chemicea

Reliable impurity analysis depends on more than obtaining a chemical name or CAS number. Structural confirmation and analytical characterization are essential for establishing confidence in the material being used.

Chemicea supports reference-standard characterization using multiple analytical techniques according to product requirements. Its standard certification package can include HPLC/GC, mass spectrometry, ^1H NMR, IR, and TGA, with additional techniques such as ^13C NMR, quantitative NMR, elemental analysis, loss on drying, and water-content testing available where relevant.

Chemicea can also provide EP or USP traceability when requested as part of the quotation and applicable analytical requirements.

This analytical approach is particularly valuable for pharmaceutical companies requiring impurity standards for method development, quality control, research, regulatory support, and impurity investigations.

Supporting Regulatory and Research Requirements

Regulatory authorities expect pharmaceutical manufacturers to adequately characterize and control impurities within APIs and finished pharmaceutical products.

For analytical teams, having access to appropriate impurity standards can simplify investigations and strengthen documentation. A well-characterized reference material can be incorporated into chromatographic studies, method validation protocols, stability investigations, and impurity identification workflows.

It is important to distinguish between a commercially supplied analytical reference standard and an official pharmacopoeial reference standard. Where a monograph specifically requires an official pharmacopoeial standard, laboratories should use the standard prescribed by the relevant pharmacopoeia. Chemicea's materials are intended for research and analytical purposes, and applicable traceability should be confirmed according to the project requirements.

Conclusion

Citalopram EP Impurity A Reference Standard is an important analytical tool for pharmaceutical laboratories involved in citalopram impurity profiling, method development, quality control, stability testing, forced-degradation studies, and analytical validation.

With CAS No. 64372-56-1, CAT No. CP-C23001, molecular formula C20H23FN2O2, and molecular weight 342.41 g/mol, the Chemicea reference standard provides pharmaceutical scientists with a defined material for investigating a specific citalopram-related compound.

Chemicea Pharmaceuticals combines impurity-standard development and supply with analytical characterization capabilities, supporting pharmaceutical manufacturers, CROs, research laboratories, and quality-control organizations worldwide. Its broader portfolio includes pharmaceutical impurities, degradation products, process impurities, nitrosamines, metabolites, glucuronides, and stable-isotope-labeled compounds.

For laboratories seeking a reliable Citalopram EP Impurity A Reference Standard for pharmaceutical analytical applications, Chemicea offers a research-focused solution backed by analytical documentation and characterization services.